Stockscreener 앱 받기
0.995
1.53%
0.015
시간 외 거래:
1.00
0.005
+0.50%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
HC Wainwright Issues Pessimistic Estimate for ONCY Earnings - MarketBeat
FY2024 Earnings Estimate for TSE:ONC Issued By HC Wainwright - MarketBeat
Leede Financial Comments on TSE:ONC FY2024 Earnings - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to Moderate Buy Rating by Leede Financial - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Upgraded at Raymond James - Defense World
Oncolytics Biotech (TSE:ONC) Upgraded by Raymond James to Moderate Buy Rating - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Downgraded to "Moderate Buy" Rating by Leede Financial - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James - MarketBeat
Research Analysts Issue Forecasts for ONCY FY2024 Earnings - Defense World
FY2028 EPS Estimates for TSE:ONC Boosted by HC Wainwright - MarketBeat
What is Raymond James' Estimate for ONCY FY2024 Earnings? - MarketBeat
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon - Baystreet.ca
Oncolytics Biotech's (ONCY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Management - GuruFocus.com
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance UK
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech® Inc. - Baystreet.ca
Oncolytics Biotech Inc reports results for the quarter ended September 30Earnings Summary - XM
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights - Nasdaq
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Nasdaq
Stocks In Play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageHere's Why - MarketBeat
International Assets Investment Management LLC Sells 24,069 Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech (TSE:ONC) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference - GuruFocus.com
Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short Interest - MarketBeat
What is Oncolytics Biotech, Inc. (ONCY) Stock Return on Shareholders’ Capital? - SETE News
Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts - Baystreet.ca
Ratio Analysis: Unpacking Oncolytics Biotech, Inc. (ONCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What was Oncolytics Biotech, Inc. (ONCY)’s performance in the last session? - US Post News
Oncolytic Virus Therapy Market Set to Witness Significant Growth by 2024-2031:Oncolytics Biotech Inc, Circio - EIN News
Stocks In Play: Oncolytics Biotech® Inc. - Barchart
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 5.3%Here's Why - MarketBeat
ONCY Stock Up on Regulatory Update From Breast Cancer Program - MSN
A new trading data show Oncolytics Biotech, Inc. (ONCY) is showing positive returns. - SETE News
Quarterly Snapshot: Quick and Current Ratios for Oncolytics Biotech, Inc. (ONCY) - The Dwinnex
Oncolytics Biotech (TSE:ONC) Shares Down 7.9%Here's Why - MarketBeat
Examining Oncolytics Biotech, Inc. (ONCY) more closely is necessary - US Post News
Oncolytics seeking FDA meeting to discuss registration-enabling study - MSN
ONCY’s 52-Week Rollercoaster: From $0.84 to $2.10 – What’s Next for Investors? - The InvestChronicle
Global cancer cases surge while biotech firms accelerate treatment innovations - Benefits and Pensions Monitor
Oncolytics targets accelerated approval for oncolytic virus therapy - Yahoo Finance
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path - The Malaysian Reserve
Oncolytics Biotech (TSE:ONC) Stock Price Up 11.8%Should You Buy? - MarketBeat
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval - TipRanks
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket - Financial Content
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low at $1.16 - Defense World
Oncolytics Biotech's SWOT analysis: pela drug potential drives stock outlook By Investing.com - Investing.com Australia
Oncolytics Biotech's SWOT analysis: pelareorep progress lifts stock outlook - Investing.com India
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
3.66%
1.11%
자본화:
|
볼륨(24시간):